Why Not in Washington?

While over 35 states have established active Rare Disease Advisory Councils (RDACs), Washington State remains frozen in legislative gridlock.

For the estimated 300,000 Washingtonians living with a rare condition, this is not merely an administrative oversight—it is a systemic failure. The absence of a council is not caused by a lack of demand or scientific capability; it is the direct result of procedural delays, fiscal nitpicking, and institutional inertia in Olympia.

The primary driver behind Washington’s failure to establish an RDAC is a repeating cycle of legislative stalls.

Bills like Senate Bill 5064 and House Bill 1238—designed to establish a 12-member advisory council within the University of Washington School of Medicine—routinely gain unanimous support in early health policy committees. Lawmakers acknowledge the problem on paper. Yet, as sessions wind down, these bills repeatedly stall in fiscal or rules committees or get pushed aside before reaching a full floor vote. Bipartisan verbal support has continuously failed to translate into prioritized floor time.

A major point of friction in Olympia has been where to house the council and who bears administrative responsibility:

• Department vs. University: Early legislative proposals sought to embed the council within the Washington State Department of Health. Later proposals shifted responsibility to the University of Washington School of Medicine.

• Bureaucratic Handoffs: Passing accountability back and forth between state executive agencies and academic institutions created prolonged debates over administrative oversight, staffing lines, and reporting structures. Rather than resolving these operational details swiftly, lawmakers have allowed structural questions to delay enactment session after session.

Compared to major state healthcare expenditures, an RDAC represents a negligible line item—primarily requiring basic staff support and travel stipends for public advisory members.

However, during tight budget cycles, state fiscal committees frequently apply hyper-scrutiny to any bill creating new advisory panels. By treating an RDAC as an "added cost" rather than a cost-saving measure—one that prevents diagnostic delays, cuts redundant testing, and streamlines Medicaid utilization—legislators repeatedly shelve the initiative to save nominal administrative funds.

In recent legislative sessions, state health committees have overwhelmingly prioritized sweeping, high-headline initiatives: broad Medicaid restructuring, public health emergency responses, behavioral health system overhauls, and general healthcare workforce shortages.

Because rare diseases are individually small in patient count, lawmakers frequently push specialized advocacy bills down the priority list. They overlook a critical truth: collectively, rare conditions affect 1 in 10 state residents, making the lack of centralized expertise a widespread policy oversight